Gout: What to Do When Acute Flare Management Does Not Achieve Full Resolution
Clinical Scenario
This protocol addresses patients with gout who require a next step after initial acute flare therapy. The objective shifts from short-term symptom relief to achieving and maintaining sustained control of serum uric acid levels.
Previous Line — Failure Condition
Acute flare management with colchicine, NSAIDs (naproxen, indomethacin), or corticosteroids (oral prednisolone, articular aspiration and corticosteroid injection) — including combination therapy with colchicine and an NSAID or colchicine and corticosteroids for multi-joint involvement — did not achieve the target of resolution of the acute gout flare with relief of joint pain and inflammation. This protocol is the structured next step.
Next-Line Approach (Partial Overview)
The approach centres on initiating urate-lowering therapy (ULT), accompanied by a defined prophylaxis strategy during the early treatment phase and targeted lifestyle modification. The full regimen — including agent, titration sequence, prophylaxis choice, and duration — is available in the complete structured protocol.
- Serum uric acid <6 mg/dL (360 mmol/L), maintained lifelong
- <5 mg/dL (300 mmol/L) for severe gout (tophi, chronic arthropathy, frequent attacks) until total crystal dissolution
- SUA should not be lowered below 3 mg/dL in the long term
References
DOI: 10.1136/annrheumdis-2016-209707
- In patients with normal kidney function, allopurinol is recommended for first-line ULT, starting at a low dose and increasing by 100 mg increments every 2–4 weeks if required, to reach the uricaemia target.
- Prophylaxis is recommended during the first 6 months of ULT.
- Recommended prophylactic treatment is colchicine; a dose that should be reduced in patients with renal impairment.
- If colchicine is not tolerated or is contraindicated, prophylaxis with NSAIDs at low dosage, if not contraindicated, should be considered.
- Every person with gout should receive advice regarding lifestyle: weight loss if appropriate and avoidance of alcohol (especially beer and spirits) and sugar-sweetened drinks, heavy meals and excessive intake of meat and seafood.
- Low-fat dairy products should be encouraged. Regular exercise should be advised.
- For patients on ULT, SUA level should be monitored and maintained to <6 mg/dL (360 mmol/L).
- A lower SUA target (<5 mg/dL; 300 mmol/L) to facilitate faster dissolution of crystals is recommended for patients with severe gout (tophi, chronic arthropathy, frequent attacks) until total crystal dissolution and resolution of gout.
- SUA <6 mg/dL (360 mmol/L) should be maintained lifelong.
- SUA level <3 mg/dL is not recommended in the long term.
View source ↗